Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mocetinostat - Mirati Therapeutics

Next Previous
Drug Profile

Mocetinostat - Mirati Therapeutics

Alternative Names: 726169-73-9; MG-0103; MGCD-0103; MGCD103; Mocetinostat dihydrobromide

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer MedImmune; Memorial Sloan-Kettering Cancer Center; MethylGene; Mirati Therapeutics; New York University School of Medicine
  • Class Antineoplastics; Benzamides; Pyrimidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Diffuse large B cell lymphoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Hodgkin's disease; Solid tumours
  • No development reported Chronic lymphocytic leukaemia; Malignant melanoma; Rhabdomyosarcoma
  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Rhabdomyosarcoma(Combination therapy, In adolescents, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (PO)
  • 26 May 2023 MethylGene and Memorial Sloan Kettering Cancer Center terminates phase II trial in Diffuse large B cell lymphoma and Follicular lymphoma (Second-line therapy or greater) in USA due to lack of accrual (NCT02282358)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top